Clicky

Lantheus Holdings, Inc.(LNTH)

Description: Lantheus Holdings, Inc. is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company's medical imaging agents are used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. The Company's products include contrast agents and medical radiopharmaceuticals, including technetium generators. The Company's products include DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, Neurolite, Thallium Tl 201, Gallium Ga 67, Gludef, Quadramet and Ablavar. The Company is also engaged in developing agents, such as Flurpiridaz F 18, which is a myocardial perfusion imaging agent; 18F LMI 1195, which is a cardiac neuronal imaging agent, and LMI 1174, which is a vascular remodeling imaging agent.


Keywords: Medicine Chemical Elements Disease Medical Imaging Prostate Cancer Medical Physics Heart Failure Stroke Post Transition Metals Gallium Artery Radiopharmaceuticals Coronary Artery Disease Artery Disease Congestive Heart Failure Perfusion Medicinal Radiochemistry Peripheral Vascular Disease Imaging Agent Neuron Perfusion Scanning Cardiovascular And Other Diseases Myocardial Perfusion Imaging

Home Page: www.lantheus.com

LNTH Technical Analysis

331 Treble Cove Road
North Billerica, MA 01862
United States
Phone: 978 671 8001


Officers

Name Title
Ms. Mary Anne Heino CEO, Pres & Director
Mr. Robert J. Marshall Jr., CFA Chief Financial Officer
Mr. Paul M. Blanchfield Chief Operating Officer
Mr. Daniel M. Niedzwiecki Sr. VP, Gen. Counsel & Corp. Sec.
Mr. Etienne Montagut Chief Bus. Officer
Ms. Andrea Sabens Chief Accounting Officer
Ms. Dorothy Barr Sr. VP of Manufacturing & Technical Operations
Mr. Mark Richard Kinarney Sr. Director of Investor Relations
Ms. Linda S. Lennox VP of Corp. Communications & Chief of Staff
Melissa Downs Director of Corp. Communications

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 31.4465
Trailing PE: 34.993
Price-to-Book MRQ: 5.8686
Price-to-Sales TTM: 4.5183
IPO Date: 2015-06-25
Fiscal Year End: December
Full Time Employees: 612
Back to stocks